| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220747 | FERRING PHARMS INC | Methods using desmopressin acetate in orodispersible form |
May, 2023
(4 months ago) | |
| US9504647 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(4 months ago) | |
| US9919025 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(4 months ago) | |
| US10307459 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(4 months ago) | |
| US7947654 | FERRING PHARMS INC | Pharmaceutical formulations |
Dec, 2023
(2 months from now) | |
| US8802624 | FERRING PHARMS INC | Methods of treatment using orodispersible desmopressin pharmaceutical formulations |
Dec, 2023
(2 months from now) | |
| US7560429 | FERRING PHARMS INC | Orodispersible dosage forms of desmopressin acetate |
Feb, 2024
(4 months from now) | |
| US11020448 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
| US10137167 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
| US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(6 years from now) | |
Nocdurna is owned by Ferring Pharms Inc.
Nocdurna contains Desmopressin Acetate.
Nocdurna has a total of 10 drug patents out of which 4 drug patents have expired.
Expired drug patents of Nocdurna are:
- US9220747
- US9504647
- US9919025
- US10307459
Nocdurna was authorised for market use on 21 June, 2018.
Nocdurna is available in tablet;sublingual dosage forms.
Nocdurna can be used as treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration, treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration, treatment of nocturia due to nocturnal polyuria in adults.
The generics of Nocdurna are possible to be released after 13 April, 2030.
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET;SUBLINGUAL
NOCDURNA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic